ARTICLE | Clinical News

Trisenox arsenic trioxide: Interim Phase II data

April 18, 2005 7:00 AM UTC

Interim data from an ongoing U.S. Phase II trial in 37 evaluable patients showed that Trisenox in combination with melphalan and vitamin C regimen (MAC) led to an objective response in 22 patients. Sp...